Clinical Trials
10 trialsNCT02688140 2026-05-29
TUD-APOLLO-064
Technische Universität Dresden
Phase 3 Completed
NCT00492856 2023-01-10
S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Phase 3 Completed
NCT00551460 2023-01-10
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00482833 2022-10-12
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Completed
NCT01404949 2021-11-30
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00413166 2019-05-07
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00276601 2014-04-17
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00003934 2013-06-05
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Completed
NCT00016159 2013-01-16
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00599937 2008-01-24
APL93: Timing of CxT and Role of Maintenance
Groupe d'etude et de travail sur les leucemies aigues promyelocytaires
Phase 3 Completed